Metrics Inc. has expanded its already robust options for enhancing drug bioavailability thanks to the recent acquisition of a BÜCHI B-290 Mini Spray Dryer.
The dryer’s core capability is rendering powder from a solution, said Brad Gold, Ph.D., vice president of pharmaceutical development. In addition, in single-unit operation, the dryer is useful for modifying particle size, agglomerating nanoparticles, drying suspensions and microencapsulation.
“Because spray drying, especially with organic solvents, is a leading technique for enhancing drug availability, this acquisition allows Metrics to offer even more drug-delivery options to our clients,” Gold said. “It also reflects Metrics’ ongoing investment in facilities and equipment to preserve our standing as the outsourcing partner of choice for contract pharmaceutical services.”
Metrics recently opened a $1.6-million, 4,524-square-foot facility specifically designed for the pre-clinical development of early formulation prototypes and related analytical methods. Working in the segregated and dedicated pre-clinical laboratory, Metrics formulators and chemists have significant autonomy to conduct development activities quickly.
The BÜCHI B-290 Mini Spray Dryer quickly and gently spray dries liquid end products to powder form, Gold said, and has the ability to handle solvents safely by providing an inert atmosphere for processing.
